CHGCF (Chugai Pharmaceutical Co) Total Stockholders Equity: $12,612 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHGCF Chugai Pharmaceutical Co Ltd CHGCF
85 GF Score
Price $43.22
GF Value $47.39
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Total Stockholders Equity?

Chugai Pharmaceutical Co CHGCF -0.84% 85 Total Stockholders Equity is $12,612 Mil as of Jun. 2026. GuruFocus rates CHGCF with a GF Score™ of 85/100 and a GF Value™ of $47.39 (Fairly Valued). The stock has 1 warning sign investors should review.

Chugai Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $12,612 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Chugai Pharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2026 was $7.66. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Chugai Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

Chugai Pharmaceutical Co  (OTCPK:CHGCF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Chugai Pharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(12612.198-0)/1645.577
=7.66

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Chugai Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 12612.198
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co Total Stockholders Equity Related Terms

Chugai Pharmaceutical Co Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co Total Stockholders Equity Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,436.50 10,557.68 11,290.20 12,362.30 12,992.54

Chugai Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13,739.47 12,782.84 12,992.54 12,022.20 12,612.20
CHGCF
85GF Score
Chugai Pharmaceutical Co Ltd CHGCF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $12,612 Mil mean?
Chugai Pharmaceutical Co (CHGCF) has a Total Stockholders Equity of $12,612 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Total Stockholders Equity too high?
Chugai Pharmaceutical Co's current Total Stockholders Equity is $12,612 Mil. Overall, Chugai Pharmaceutical Co has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Total Stockholders Equity compare to LLY and JNJ?
Chugai Pharmaceutical Co's Total Stockholders Equity of $12,612 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Total Stockholders Equity is $12,612 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Fairly Valued. The stock's GF Value™ is $47.39, compared to a current price of $43.22 — trading 8.8% below its estimated fair value. The current Total Stockholders Equity is $12,612 Mil. Chugai Pharmaceutical Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current Total Stockholders Equity is $12,612 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of $43.22 is trading 8.8% below its estimated GF Value™ of $47.39. GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for CHGCF:

  • Total Stockholders Equity: $12,612 Mil
  • GF Value™: $47.39 vs. price of $43.22 (8.8% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
85GF Score

Get the complete analysis for CHGCF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.22
Price
$47.39
GF Value